Stockscreener 앱 받기
0.6702
3.57%
-0.0248
시간 외 거래:
.70
0.0298
+4.45%
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Lineage Cell Therapeutics Inc [LCTX] Shares Fall Approximately -33.17% Over the Year - Knox Daily
BlackRock, Inc. Increases Stake in Lineage Cell Therapeutics Inc. - GuruFocus.com
Stem Cell Therapy Market Types, Applications, Share, Growth - openPR
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference - BioSpace
Lineage Cell Therapeutics Inc (LCTX) Stock: Navigating a Year of Volatility - The InvestChronicle
Cell Therapy Pioneer Lineage to Showcase Latest Neurological Breakthroughs at Major Healthcare Conference - StockTitan
Lineage Cell Therapeutics Inc (LCTX) stock on the rise: An overview - US Post News
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from HC Wainwright - MarketBeat
Market Recap Check: Lineage Cell Therapeutics Inc (LCTX)’s Negative Finish at 0.60, Up/Down -4.12 - The Dwinnex
Defender Capital LLC. Has $3 Million Stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Cell Therapeutics’ (LCTX) Buy Rating Reiterated at HC Wainwright - Defense World
Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics - Benzinga
Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Broadwood Partners acquires $6 million in Lineage Cell Therapeutics shares By Investing.com - Investing.com Canada
Broadwood Partners acquires $6 million in Lineage Cell Therapeutics shares - Investing.com
JPMorgan Chase & Co. Boosts Stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering - BioSpace
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - The Malaysian Reserve
Barclays PLC Boosts Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Short Interest in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Rises By 13.5% - MarketBeat
Cell Therapy Manufacturing Market Trends, Innovations, - openPR
Jane Street Group LLC Cuts Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Maxim Group Has Lowered Expectations for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World
Growth Trends in the Induced Pluripotent Stem Cells (iPSCs) Market, 2024-2035: A Forecasted $5.6 Billion Landscape - GlobeNewswire
Barclays PLC Increases Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Geode Capital Management LLC Raises Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Issues Letter to Stockholders - BioSpace
Lineage Cell Therapeutics outlines 2025 strategy - Investing.com
Lineage Cell Therapeutics Secures $30M Funding, Extends Runway to 2027 for Cell Therapy Pipeline - StockTitan
Cell Therapy Manufacturing Market Generated Opportunities, - openPR
Lineage Cell price target lowered to $2 from $3 at D. Boral Capital - Yahoo Finance
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital - Defense World
The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts - Benzinga
D. Boral Capital Reiterates Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - MarketBeat
State Street Corp Acquires 45,483 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Here’s Why Lineage Cell Therapeutics Inc (AMEX: LCTX) Is An Attractive Investment Right Now - Stocks Register
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1%Here's What Happened - MarketBeat
Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround - Yahoo Finance
BioTime, Inc. : BioTime and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards® Version 3.08 - Marketscreener.com
LCTX stock touches 52-week low at $0.5 amid market challenges - Investing.com
Cell Therapy Manufacturing Market Growth in Future Scope - openPR
Lineage Cell Therapeutics FY2024 EPS Lifted by HC Wainwright - MarketBeat
HC Wainwright Issues Positive Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World
Stem cell therapy companies take different roads to reproducibility - BioCentury
Lineage Cell Therapeutics stock rating holds at Buy, Phase 2a data sparks target rise - Investing.com
Is Lineage (LINE) the Best New Pick in Brad Gerstner’s Portfolio? - Yahoo Finance
1.03%
자본화:
|
볼륨(24시간):